R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

The 5th Operationalize Expanded Access Programs banners

Partner Content

Returning... The 5th Operationalize Expanded Access Programs...

Welcome to, or welcome back to, the 5th Operationalize: Expanded Access Programs Summit 2025!

R&D

Growing threat of AMR: UN calls for urgent global action

In response to the rise of AMR, world leaders recently convened at the United Nations General Assembly to forge a landmark commitment, setting ambitious targets and funding initiatives to c

R&D

Webinar recap: Boosting recruitment and retention with SDOH ...

As the pharmaceutical industry continues its shift towards more patient-centric models, the incorporation of social determinants of health (SDOH) data has become increasingly valuable.

R&D

Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.

R&D

From neurosurgery to focused ultrasound: Not if, but when

Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high.

R&D

Viva in vivo: The next generation of cell therapy is fast ap...

Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a pati